Mechanisms, Effects, and Management of Neurological Complications of Post-Acute Sequelae of COVID-19 (NC-PASC)

With a growing number of patients entering the recovery phase following infection with SARS-CoV-2, understanding the long-term neurological consequences of the disease is important to their care. The neurological complications of post-acute sequelae of SARS-CoV-2 infection (NC-PASC) represent a myriad of symptoms including headaches, brain fog, numbness/tingling, and other neurological symptoms that many people report long after their acute infection has resolved. Emerging reports are being published concerning COVID-19 and its chronic effects, yet limited knowledge of disease mechanisms has challenged therapeutic efforts. To address these issues, we review broadly the literature spanning 2020–2022 concerning the proposed mechanisms underlying NC-PASC, outline the long-term neurological sequelae associated with COVID-19, and discuss potential clinical interventions.

[1]  S. Pittaluga,et al.  SARS-CoV-2 infection and persistence in the human body and brain at autopsy , 2022, Nature.

[2]  Z. Al-Aly,et al.  Long-term neurologic outcomes of COVID-19 , 2022, Nature Medicine.

[3]  P. Lotufo,et al.  Molecular and pro-inflammatory aspects of COVID-19: The impact on cardiometabolic health , 2022, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.

[4]  V. Sehgal,et al.  Myelitis Following COVID-19 Illness , 2022, Cureus.

[5]  E. Wan,et al.  Post-COVID-19 Condition. , 2022, Annual review of medicine.

[6]  S. Efrati,et al.  Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial , 2022, Scientific Reports.

[7]  T. Kent,et al.  SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations , 2022, Ageing Research Reviews.

[8]  J. Patcai Is ‘Long Covid’ similar to ‘Long SARS’? , 2022, Oxford open immunology.

[9]  O. Watson,et al.  Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.

[10]  J. Lieberman,et al.  FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation , 2022, Nature.

[11]  T. Pollak,et al.  Neuroimmune disorders in COVID-19 , 2022, Journal of Neurology.

[12]  R. Bordet,et al.  Long-term cognitive impairments following COVID-19: a possible impact of hypoxia , 2022, Journal of Neurology.

[13]  Thomas E. Nichols,et al.  SARS-CoV-2 is associated with changes in brain structure in UK Biobank , 2022, Nature.

[14]  V. Balasubramaniam,et al.  Host Molecules Regulating Neural Invasion of Zika Virus and Drug Repurposing Strategy , 2022, Frontiers in Microbiology.

[15]  J. Olmos,et al.  Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study , 2022, Current medical research and opinion.

[16]  B. Jarrott,et al.  “LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy , 2022, Pharmacology research & perspectives.

[17]  Maria Papadopoulou,et al.  Neurological manifestations of long-COVID syndrome: a narrative review , 2022, Therapeutic advances in chronic disease.

[18]  Nelson B Rodrigues,et al.  Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis , 2021, Brain, Behavior, and Immunity.

[19]  F. Kobeissy,et al.  SARS-CoV-2 involvement in central nervous system tissue damage , 2021, Neural regeneration research.

[20]  Xiao Li,et al.  SARS-CoV-2 Causes Mitochondrial Dysfunction and Mitophagy Impairment , 2022, Frontiers in Microbiology.

[21]  T. Robbins,et al.  Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. , 2021, Clinical medicine.

[22]  H. Zhou,et al.  Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb , 2021, Cell.

[23]  Hai Wang,et al.  Predictors of Mortality in Hospitalized COVID-19 Patients Complicated With Hypotension and Hypoxemia: A Retrospective Cohort Study , 2021, Frontiers in Medicine.

[24]  M. Kivipelto,et al.  Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions , 2021, Journal of Neurology.

[25]  M. Kubo,et al.  SARS-CoV-2 infection causes immunodeficiency in recovered patients by downregulating CD19 expression in B cells via enhancing B-cell metabolism , 2021, Signal Transduction and Targeted Therapy.

[26]  Edith Fabiola Mendez Elizondo,et al.  Central Nervous System Injury in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: MRI Findings , 2021, Cureus.

[27]  Urvish K. Patel,et al.  Post‐acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis , 2021, Journal of medical virology.

[28]  N. Rezaei,et al.  Autoimmune complications of COVID‐19 , 2021, Journal of medical virology.

[29]  Molly A Brady,et al.  SARS-CoV-2: is there neuroinvasion? , 2021, Fluids and barriers of the CNS.

[30]  H. Schiöth,et al.  Neurological manifestations of COVID-19: A comprehensive literature review and discussion of mechanisms , 2021, Journal of Neuroimmunology.

[31]  S. Basu,et al.  Seizure after recovery from Covid-19 , 2021, Journal of family medicine and primary care.

[32]  L. McCullough,et al.  The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection , 2021, Current Neurology and Neuroscience Reports.

[33]  S. Jonjić,et al.  Cytomegalovirus Infection and Inflammation in Developing Brain , 2021, Viruses.

[34]  S. Yong Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments , 2021, Infectious diseases.

[35]  Z. Shabani Demyelination as a result of an immune response in patients with COVID-19 , 2021, Acta Neurologica Belgica.

[36]  T. L. Wong,et al.  Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—A Systemic Review and Comparison of Clinical Presentation and Symptomatology , 2021, Medicina.

[37]  R. Jayadevan,et al.  Long COVID: An overview , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[38]  A. Simpkins,et al.  Post-COVID seizure: A new feature of “long-COVID” , 2021, eNeurologicalSci.

[39]  S. Birring,et al.  Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses , 2021, The Lancet Respiratory Medicine.

[40]  Abdullah Al Nahid,et al.  Silent hypoxia in COVID-19: pathomechanism and possible management strategy , 2021, Molecular Biology Reports.

[41]  V. Abedi,et al.  Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology , 2021, Frontiers in Cardiovascular Medicine.

[42]  Ryan D. Chow,et al.  Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms , 2021, Cell Reports Medicine.

[43]  J. Min,et al.  SARS-CoV-2 cell tropism and multiorgan infection , 2021, Cell discovery.

[44]  C. Taylor,et al.  Persistent neurologic symptoms and cognitive dysfunction in non‐hospitalized Covid‐19 “long haulers” , 2021, Annals of clinical and translational neurology.

[45]  D. Brodie,et al.  Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[46]  K. Melmed,et al.  A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications , 2021, Journal of the Neurological Sciences.

[47]  Zhang Yan,et al.  What can cerebrospinal fluid testing and brain autopsies tell us about viral neuroinvasion of SARS-CoV-2. , 2021, Journal of medical virology.

[48]  David A. Drew,et al.  Attributes and predictors of long COVID , 2021, Nature Medicine.

[49]  Milad Asgari Mehrabadi,et al.  COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler: Looking for Clarity in the Haze of the Pandemic , 2021, medRxiv.

[50]  W. Banks,et al.  Interactions of SARS-CoV-2 with the Blood–Brain Barrier , 2021, International journal of molecular sciences.

[51]  A. Duits,et al.  Neurologic sequelae of severe chikungunya infection in the first 6 months of life: a prospective cohort study 24-months post-infection , 2021, BMC Infectious Diseases.

[52]  L. Østergaard SARS CoV‐2 related microvascular damage and symptoms during and after COVID‐19: Consequences of capillary transit‐time changes, tissue hypoxia and inflammation , 2021, Physiological reports.

[53]  E. Playford,et al.  Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline , 2021, BMJ.

[54]  S. Villapol,et al.  More than 50 long-term effects of COVID-19: a systematic review and meta-analysis , 2021, Scientific Reports.

[55]  R. Kream,et al.  Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes that Favor Viral Survival , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[56]  S. Saffari,et al.  Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis of Incidence, Outcomes and Predictors , 2020, Journal of Stroke and Cerebrovascular Diseases.

[57]  I. Solomon,et al.  What can we learn from brain autopsies in COVID-19? , 2020, Neuroscience Letters.

[58]  Ryan J. Low,et al.  Characterizing long COVID in an international cohort: 7 months of symptoms and their impact , 2020, EClinicalMedicine.

[59]  Q. Lu,et al.  COVID-19 and autoimmune diseases , 2020, Current opinion in rheumatology.

[60]  C. Conrad,et al.  Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19 , 2020, Nature Neuroscience.

[61]  A. Aguzzi,et al.  Intracerebral endotheliitis and microbleeds are neuropathological features of COVID‐19 , 2020, Neuropathology and applied neurobiology.

[62]  R. Sutton,et al.  Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. , 2020, Clinical medicine.

[63]  E. Wood,et al.  Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS-CoV-2 ‘long-haulers’? , 2020, Chronic Diseases and Translational Medicine.

[64]  W. Heywood,et al.  'The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. , 2020, F1000Research.

[65]  P. Gaur,et al.  Cerebral microhaemorrhage in COVID-19: a critical illness related phenomenon? , 2020, Stroke and vascular neurology.

[66]  A. Khakshour,et al.  VIRAL MENINGITIS ASSOCIATED WITH COVID-19 IN A 9-YEAR-OLD CHILD: A CASE REPORT. , 2020, The Pediatric infectious disease journal.

[67]  A. Baig Chronic COVID syndrome: Need for an appropriate medical terminology for long‐COVID and COVID long‐haulers , 2020, Journal of medical virology.

[68]  F. Nikbakht,et al.  How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms , 2020, Multiple Sclerosis and Related Disorders.

[69]  I. Alquisiras-Burgos,et al.  Neurological Complications Associated with the Blood-Brain Barrier Damage Induced by the Inflammatory Response During SARS-CoV-2 Infection , 2020, Molecular Neurobiology.

[70]  S. Naz,et al.  Meningitis as an Initial Presentation of COVID-19: A Case Report , 2020, Frontiers in Public Health.

[71]  E. Gulbins,et al.  Sphingosine prevents binding of SARS–CoV-2 spike to its cellular receptor ACE2 , 2020, The Journal of Biological Chemistry.

[72]  G. Lippi,et al.  Lymphopenia and neutrophilia at admission predicts severity and mortality in patients with COVID-19: a meta-analysis , 2020, Acta bio-medica : Atenei Parmensis.

[73]  M. Garcia-Gil,et al.  SARS-CoV-2 Infection: A Role for S1P/S1P Receptor Signaling in the Nervous System? , 2020, International journal of molecular sciences.

[74]  Vasuki H. Dandu,et al.  Coronavirus Disease 2019 in Patients With Prior Ischemic Stroke , 2020, Cureus.

[75]  T. Greenhalgh,et al.  Management of post-acute covid-19 in primary care , 2020, BMJ.

[76]  S. Salinas,et al.  Neurocognitive impacts of arbovirus infections , 2020, Journal of Neuroinflammation.

[77]  A. Paetau,et al.  Neuropathologic features of four autopsied COVID‐19 patients , 2020, Brain pathology.

[78]  K. Melmed,et al.  Cerebral Microbleeds and Leukoencephalopathy in Critically Ill Patients With COVID-19 , 2020, Stroke.

[79]  H. Ejaz,et al.  COVID-19 and comorbidities: Deleterious impact on infected patients , 2020, Journal of Infection and Public Health.

[80]  C. de Waure,et al.  Long-Term Clinical, Audiological, Visual, Neurocognitive and Behavioral Outcome in Children With Symptomatic and Asymptomatic Congenital Cytomegalovirus Infection Treated With Valganciclovir , 2020, Frontiers in Medicine.

[81]  D. Pugin,et al.  COVID‐19 is Associated with an Unusual Pattern of Brain Microbleeds in Critically Ill Patients , 2020, Journal of Neuroimaging.

[82]  S. Farhadian,et al.  Neuroinvasion of SARS-CoV-2 in human and mouse brain , 2020, bioRxiv.

[83]  D. Ragab,et al.  The COVID-19 Cytokine Storm; What We Know So Far , 2020, Frontiers in Immunology.

[84]  Pardis C Sabeti,et al.  Neuropathological Features of Covid-19 , 2020, The New England journal of medicine.

[85]  J. Gómez-Arnau,et al.  Covid-19 treatment-induced neuropsychiatric adverse effects , 2020, General Hospital Psychiatry.

[86]  J. Bayry,et al.  Autoimmune and inflammatory diseases following COVID-19 , 2020, Nature Reviews Rheumatology.

[87]  S. Farhadian,et al.  Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. , 2020, JAMA neurology.

[88]  N. Trotta,et al.  Early postmortem brain MRI findings in COVID-19 non-survivors , 2020, Neurology.

[89]  J. Marini,et al.  Management of COVID-19 Respiratory Distress. , 2020, JAMA.

[90]  S. Pavlakis,et al.  Encephalitis Associated with COVID-19 Infection in an 11-Year-Old Child , 2020, Pediatric Neurology.

[91]  R. M. Barrientos,et al.  The impact of nutrition on COVID-19 susceptibility and long-term consequences , 2020, Brain, Behavior, and Immunity.

[92]  R. Butowt,et al.  SARS-CoV-2: Olfaction, Brain Infection, and the Urgent Need for Clinical Samples Allowing Earlier Virus Detection , 2020, ACS chemical neuroscience.

[93]  Haibo Xu,et al.  Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19 , 2020, Journal of Infection.

[94]  T. Lv,et al.  Encephalitis as a clinical manifestation of COVID-19 , 2020, Brain, Behavior, and Immunity.

[95]  N. Enomoto,et al.  A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 , 2020, International Journal of Infectious Diseases.

[96]  Robert J. Mason,et al.  Pathogenesis of COVID-19 from a cell biologic perspective , 2020, European Respiratory Journal.

[97]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[98]  E. Ely,et al.  Long-term cognitive impairment after acute respiratory distress syndrome: a review of clinical impact and pathophysiological mechanisms , 2019, Critical Care.

[99]  S. Ferreira,et al.  Zika virus replicates in adult human brain tissue and impairs synapses and memory in mice , 2019, Nature Communications.

[100]  B. Lidbury,et al.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review , 2019, Diagnostics.

[101]  Alexa B. R. McIntyre,et al.  Altered m6A modification of specific cellular transcripts affects Flaviviridae infection , 2019, bioRxiv.

[102]  G. Ippolito,et al.  Tropism of the Chikungunya Virus , 2019, Viruses.

[103]  L. Kedzierski,et al.  Flavivirus Receptors: Diversity, Identity, and Cell Entry , 2018, Front. Immunol..

[104]  Z. Chavoshzadeh,et al.  Neurological Manifestations of Primary Immunodeficiencies , 2018, Iranian journal of child neurology.

[105]  S. Irani,et al.  Tocilizumab-associated multifocal cerebral thrombotic microangiopathy. , 2016, Neurology. Clinical practice.

[106]  P. Garcez,et al.  Zika virus impairs growth in human neurospheres and brain organoids , 2016, Science.

[107]  R. Cohrs,et al.  A comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivation. , 2015, The Journal of general virology.

[108]  Anand Viswanathan,et al.  Cerebral microbleeds: overview and implications in cognitive impairment , 2014, Alzheimer's Research & Therapy.

[109]  A. Tselis Epstein-Barr virus infections of the nervous system. , 2014, Handbook of clinical neurology.

[110]  R. Rossaint,et al.  Neurological outcome after experimental lung injury , 2011, Respiratory Physiology & Neurobiology.

[111]  B. Stainsby,et al.  Neuromusculoskeletal disorders following SARS: a case series. , 2011, The Journal of the Canadian Chiropractic Association.

[112]  Mei-Ru Chen Epstein–Barr Virus, the Immune System, and Associated Diseases , 2011, Front. Microbio..

[113]  M. Albert,et al.  Biology and pathogenesis of chikungunya virus , 2010, Nature Reviews Microbiology.

[114]  G. Jahn,et al.  Cytomegalovirus cell tropism. , 2008, Current topics in microbiology and immunology.

[115]  P. Kennedy,et al.  The neurotropic herpes viruses: herpes simplex and varicella-zoster , 2007, The Lancet Neurology.

[116]  Jiang Gu,et al.  Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.

[117]  C. Prober,et al.  Pathogenesis and disease , 2007 .

[118]  D. Tirschwell,et al.  Long-term neurological complications after hypoxic-ischemic encephalopathy. , 2006, Seminars in neurology.

[119]  Zhang Zai-qian Epstein-Barr Virus and Neurological Diseases , 2006 .

[120]  B. Sellhaus,et al.  S-100 Protein and Neurohistopathologic Changes in a Porcine Model of Acute Lung Injury , 2005, Anesthesiology.

[121]  L. Schaade,et al.  Neurological complications of acute and persistent Epstein‐Barr virus infection in paediatric patients , 2002, Journal of medical virology.

[122]  C P Das,et al.  Neurological complications of HIV infection. , 1998, Neurology India.

[123]  H. Gendelman,et al.  Human Immunodeficiency Virus Neurotropism: an Analysis of Viral Replication and Cytopathicity for Divergent Strains in Monocytes and Microglia , 1998, Journal of Virology.

[124]  L. Weiner,et al.  Acute manifestations and neurologic sequelae of Epstein-Barr virus encephalitis in children. , 1996, The Pediatric infectious disease journal.

[125]  N. Stocchetti,et al.  Hypoxemia and arterial hypotension at the accident scene in head injury. , 1996, The Journal of trauma.

[126]  J. McCutchan Cytomegalovirus infections of the nervous system in patients with AIDS. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[127]  R. Levy,et al.  The neurologic complications of human immunodeficiency virus infection. , 1993, The Medical clinics of North America.

[128]  A. M. Ramsay,et al.  Myalgic encephalomyelitis--a persistent enteroviral infection? , 1990, Postgraduate medical journal.

[129]  P. Behan,et al.  The postviral fatigue syndrome--an analysis of the findings in 50 cases. , 1985, The Journal of infection.

[130]  H. Stern Cytomegalovirus Infection * , 1975, The British journal of clinical practice.

[131]  B. Hemmer,et al.  COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients Case Series , 2022 .